NYSE:EW • US28176E1082
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EDWARDS LIFESCIENCES CORP (EW).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-27 | Barclays | Maintains | Overweight -> Overweight |
| 2026-04-24 | BTIG | Maintains | Buy -> Buy |
| 2026-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-04-24 | Truist Securities | Maintains | Hold -> Hold |
| 2026-04-24 | Baird | Maintains | Neutral -> Neutral |
| 2026-04-24 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2026-04-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-04-06 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-11 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-11 | Truist Securities | Maintains | Hold -> Hold |
| 2026-02-11 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-02-11 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-01-20 | Stifel | Maintains | Buy -> Buy |
| 2026-01-20 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-12 | UBS | Maintains | Neutral -> Neutral |
| 2026-01-12 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-09 | TD Cowen | Upgrade | Hold -> Buy |
| 2026-01-07 | Stifel | Maintains | Buy -> Buy |
| 2025-12-18 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-12-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-12-16 | Baird | Maintains | Neutral -> Neutral |
| 2025-12-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-05 | BTIG | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.01B 12.23% | 5.44B 8.57% | 6.068B 11.55% | 6.88B 13.39% | 7.555B 9.81% | 8.308B 9.97% | 9.016B 8.52% | 9.887B 9.66% | 11.353B 14.83% | 12.602B 11.00% | |
| EBITDA YoY % growth | 1.657B -3.34% | 1.635B -1.33% | 1.805B 10.40% | 2.149B 19.04% | 2.404B 11.87% | 2.673B 11.19% | 2.92B 9.24% | 3.354B 14.86% | 3.837B 14.40% | 4.31B 12.33% | |
| EBIT YoY % growth | 1.512B -3.97% | 1.48B -2.14% | 1.649B 11.39% | 1.968B 19.37% | 2.208B 12.20% | 2.496B 13.04% | 2.736B 9.62% | 3.041B 11.15% | 3.554B 16.87% | 3.995B 12.41% | |
| Operating Margin | 30.19% | 27.21% | 27.17% | 28.60% | 29.23% | 30.04% | 30.35% | 30.76% | 31.30% | 31.70% | |
| EPS YoY % growth | 2.51 1.21% | 2.62 4.38% | 2.56 -2.29% | 3.01 17.69% | 3.37 11.96% | 3.80 12.59% | 4.27 12.49% | 4.69 9.85% | 5.33 13.46% | 5.95 11.80% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.76 13.88% | 0.77 15.04% | 0.76 30.77% | 0.81 4.44% | 0.86 12.42% | 0.86 12.13% | 0.86 13.82% |
| Revenue Q2Q % growth | 1.75B 14.21% | 1.733B 11.58% | 1.762B 12.26% | 1.794B 8.82% | 1.89B 8.00% | 1.898B 9.52% | 1.934B 9.76% |
| EBITDA Q2Q % growth | 541.6M 7.12% | 544.17M -1.33% | 531.18M 0.81% | 575.65M 8.27% | 602.59M 11.26% | 611.41M 12.36% | 615.03M 15.79% |
| EBIT Q2Q % growth | 493.13M 14.44% | 496.78M 13.52% | 488.61M 31.95% | 526.62M 2.32% | 553.73M 12.29% | 558.45M 12.41% | 571.24M 16.91% |
All data in USD
43 analysts have analysed EW and the average price target is 97.95 USD. This implies a price increase of 17.36% is expected in the next year compared to the current price of 83.46.
EDWARDS LIFESCIENCES CORP (EW) will report earnings on 2026-07-22, after the market close.
The consensus EPS estimate for the next earnings of EDWARDS LIFESCIENCES CORP (EW) is 0.76 USD and the consensus revenue estimate is 1.75B USD.
The expected long term growth rate for EDWARDS LIFESCIENCES CORP (EW) is 10.15%.